title: Clinical Insights Into the Biology and Treatment of Pancreatic Cancer.
abstract: Pancreatic cancer is a devastating disease with a universally poor prognosis. In 2015, it is estimated that there will be 48,960 new cases of pancreatic cancer and that 40,560 people will die of the disease. The 5-year survival rate is 7.2% for all patients with pancreatic cancer; however, survival depends greatly on the stage at diagnosis. Unfortunately, 53% of patients already have metastatic disease at diagnosis, which corresponds to a 5-year survival rate of 2.4%. Even for the 9% of patients with localized disease confined to the pancreas, the 5-year survival is still modest at only 27.1%. These grim statistics highlight the need for ways to identify cohorts of individuals at highest risk, methods to screen those at highest risk to identify preinvasive pathologic precursors, and development of effective systemic therapies. Recent clinical and translational progress has emphasized the relationship with diabetes, the role of the stroma, and the interplay of each of these with inflammation in the pathobiology of pancreatic cancer. In this article, we will discuss these relationships and how they might translate into novel management strategies for the treatment of this disease.
authors.affiliation: Duke University Medical Center, Durham, NC niharika.mettu@duke.edu.
authors.forename: Niharika B
authors.initials: NB
authors.lastname: Mettu
authors.affiliation: Duke University Medical Center, Durham, NC.
authors.forename: James L
authors.initials: JL
authors.lastname: Abbruzzese
mesh_terms: D002471:Cell Transformation, Neoplastic; D003131:Combined Modality Therapy; D003920:Diabetes Mellitus / Q000453:epidemiology / Q000378:metabolism; D019468:Disease Management; D006801:Humans; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D012307:Risk Factors; D017154:Stromal Cells / Q000378:metabolism / Q000473:pathology